

Analysis of the Advantages of and Barriers to Adoption of SMART MANUFACTURING FOR MEDICAL PRODUCTS

An industry study by MxD and IAAE between February and June 2021 funded by FDA Office of Counterterrorism and Emerging ThreatsA

PROJECT SUMMARY



Project Objectives

Gain an initial baseline to deepen FDA's understanding of the factors that impact a manufacturer's decision to invest in and adopt digital technologies by illuminating both perceived and demonstrated barriers from technical, business, and regulatory perspectives, and related cybersecurity considerations.



Key Activities

Detailed evaluations at nine US-based, FDA-regulated pharma sites covering:

- Business process factors
- Technology factors
- Regulatory factors
- People factors



DeliverablesA


Project report and de-identified data for distribution within FDA

Project exec summary and infographic for limited distribution


"The reality is that it isn't enough to just respond to the current pandemic. The FDA and industry have to accelerate the adoption of advanced and smart manufacturing technologies to strengthen the nation's public health infrastructure."

Stephen M. Hahn, M.D., Former Commissioner of Food and Drug Administration, 2019-2021

What position do you currently hold within the organization you represent?A



What type of manufacturing do you carry out at your site?A




31 participants represented the US-based sites of 9 different manufacturers. While the sample size of manufacturers was limited, most sites were represented by several participants, the majority in director level roles, and each participant completed a survey and two separate interviews with the project team.

BARRIERS TO TECHNOLOGY ADOPTION (REAL AND PERCEIVED)

This engagement was seen by the manufacturers interviewed to be a very welcome initiative coming from FDA.

REAL BARRIERS

Respondents were asked to rank in priority from top to bottom the factors that, in their opinion, most hinder digital transformation at their site.



Obstacles to Digital Transformation. Business Process respondents (n=7)

LIKELY PERCEIVED BARRIERSA

The misunderstanding that a corporate approach to Operational Excellence is sufficient and does not need to be complemented by best practices and expertise from the disciplines of change management and human performance.

The technology gap is sometimes a psychological one. Lack of understanding of technologies or the inability of experts to adequately explain technologies can cause individuals to be more reluctant to adopt/trust new technology. Whether this is a real or perceived barrier is most likely person and culture dependent and may be reduced with education, training, and skills.

The perception that regulation may be a limitation. Regular engagement of regulators and internally presenting the value of proposed changes can mitigate this.

That new expertise depends on the infusion of talent through new hires. Capability building through technical training and educational programs among internal talent. In a labor market that is already not producing enough talent to hire, this perceived barrier could be detrimental to the long-term success of the organization and lead to challenges with talent retention.


WHAT WE EXPECTED TO FIND

The levels of digital mastery of pharmaceutical manufacturers were found to have broadly improved when compared to a similar assessment done a few years ago which placed the pharmaceutical industry firmly in the Beginners quadrant. Such progress is likely due to the emphasis placed on digital transformation in recent years, and likely further accelerated by the pandemic.

Project team findings under MxD-IAAE FDA OCET study 22FEB21 - 23JUN21 (n=7)

Source: Leading Digital, by Westerman, George, Bonnet, Didier, McAfee, Andrew. Harvard Business Review Press. Level of digital mastery (all participating manufacturers that completed business process surveys) (n=7). Used with permission of the publisher

FOUR LEVELS OF DIGITAL MASTERYA



Several individual companies are progressing through Levels 2 and 3 of the BioPhorum Digital Plant Maturity Model, shown in the table below. However, the overall picture is that the majority of manufacturers assessed are only starting to emerge into levels 2 and 3, and many are still highly reliant on paper-centric processes at Level 1.

BioPhorum Digital Plant Maturity Model


Emerging - partially describes my plant
Mature - fully describes my plant OR plant matured past this level

Dimension of Maturity	Trend	Level 1 Pre-Digital Plant	Level 2 Digital Silos	Level 3 Connected Plant	Level 4 Predictive Plant	Level 5 Adaptive Plant
Manufacturing Execution & Process Automation	UP	Mature	Emerging	Emerging	None	None
Lab Execution & Quality Management	UP	Emerging	Emerging	Emerging	Emerging	None
Manufacturing Support	UP	Emerging	Emerging	Emerging	None	None
Production Planning & Supply Chain	UP	Emerging	Emerging	Emerging	None	None
People & Culture	UP	Emerging	Emerging	Emerging	Emerging	None
Business Insights & Analytics	UP	Emerging	Emerging	Emerging	None	None
Systems Interoperability & Governance	UP	Mature	Emerging	Emerging	Emerging	None
IT Security & Operations	UP	Mature	Mature	Emerging	Emerging	None

Source: Digital Plant Maturity Model Summary across manufacturers assessed (n=9). DPMM used with permission of BioPhorum

Level 1 | Pre-digital plant: manual, paper-based processes
Level 2 | Digital silos: islands of automation
Level 3 | Connected plant: high level of automation and systems standardization
Level 4 | Predictive plant: integrated plant network, pervasive real-time predictive analytics
Level 5 | Adaptive plant: plant of the future, autonomous, self-optimizing, plug-and-play

WHAT WE DID NOT EXPECT TO FIND



Digital transformation compass

Average across all manufacturers who completed business process surveys with max and min scores shown in gray shading for each segment


Project team findings under MxD-IAAE FDA OCET study, 22FEB21 - 23JUN21 (n=7)

- 21 Maximum possible score
- 16 Well positioned if above this point
- 8 Significant action is needed if below this point
- 3 Minimum possible score

Source: Leading Digital, by Westerman, George, Bonnet, Didier, McAfee, Andrew. Harvard Business Review Press. Part III Digital Transformation Compass used with permission of the publisher.

THREE AREAS MANUFACTURERS CAN BETTER FOCUS THEIR ENGAGEMENT WITH FDA

- 01** Avail of the webinars, podcasts, conferences, and seminars that FDA make available or attend, not just for your regulatory intelligence needs but for quality and regulatory colleagues throughout your organization.
- 02** Understand how to engage the FDA for early discussions for adopting advanced technologies through CDER, CBER and CDRH initiatives like the ETT, CATT, and CQVIP (links below).
- 03** If applicable, access CDRH Learn, FDA's Center for Devices and Radiological Health (CDRH) web page for multimedia industry education and subscribe to Twitter or other channels to stay informed on new media releases.



If your organization would like to connect with the MxD team reach out via the Web.A > MxD

Similarly, to connect with the IAAE team reach out via LinkedIn.A > IAAE

MxD Team - Daniel Reed, Tony Del Sesto, Paul Pierson
IAAE Team - Mike Hourigan, Malcolm Jeffers, Scott Sommer, McCaig Dove, Ben Faiga
Source: Accelerating the Adoption of Advanced Manufacturing Technologies to Strengthen Our Public Health Infrastructure 01/15/2021
> FDA Office of Counterterrorism and Emerging Threats
> FDA Center for Biologics Evaluation and Research (CBER) Advanced Technologies Program (CATT)
> FDA Center for Drug Evaluation and Research (CDER) Emerging Technology Program (ETT)
> FDA Center for Devices and Radiological Health (CDRH) Learn
> FDA Center for Devices and Radiological Health (CDRH) Case for Quality Voluntary Improvement Program (CQVIP)
> National Academies of Sciences, Engineering, and Medicine 2021. Innovations in Pharmaceutical Manufacturing on the Horizon: Technical Challenges, Regulatory Issues, and Recommendations. Washington, DC: The National Academies Press

The analyses upon which this publication is based were performed under Contract Number 75F40120P00303, entitled, "Analysis of the Advantages of and Barriers to Adoption of Smart Manufacturing for Medical Products," sponsored by the Food and Drug Administration, Department of Health and Human Services.